The Times Australia
The Times World News

.

A major ivermectin study has been withdrawn, so what now for the controversial drug?

  • Written by Andrew McLachlan, Head of School and Dean of Pharmacy, University of Sydney
A major ivermectin study has been withdrawn, so what now for the controversial drug?

Ivermectin[1], an existing drug against parasites including head lice, has had a chequered history when it comes to treating COVID-19.

The bulk of studies so far show there’s not enough evidence[2] ivermectin is useful in treating or preventing COVID-19, either alone or with antibiotics or supplements.

Yet interest in the drug remains, on social media, in some countries, with some doctors[3] and with one politician in particular, Liberal MP Craig Kelly, touting its benefits[4].

Now a large clinical trial that seemed to show positive results for ivermectin has been withdrawn[5]. So you’d think that would be end of the ivermectin saga.

But research into ivermectin is ongoing. Here’s what the evidence says so far and what we can expect next.

Read more: How to deal with the Craig Kelly in your life: a guide to tackling coronavirus contrarians[6]

How was ivermectin even a contender?

Ivermectin was identified as a potential COVID-19 treatment based on experiments in isolated cells[7] and animals[8]. The initial lab studies into ivermectin’s effect on the coronavirus involved very high concentrations[9] of the drug. These were many times higher than can be achieved in the body at doses recommended to treat parasites.

As the pandemic progressed, so did ivermectin clinical trials. But when experts who write doctors’ prescribing guidelines reviewed the data, they found not enough evidence to back ivermectin to treat or prevent COVID-19. These groups included Australia’s National COVID-19 Clinical Evidence Taskforce[10] and the World Health Organization[11]. Instead, they said ivermectin should only be used in clinical trials[12].

Read more: Ivermectin is still not a miracle cure for COVID-19, despite what you may have read[13]

The most robust summary of the evidence[14] for ivermectin in COVID-19, published in June, goes one step further. It found available evidence showed ivermectin didn’t work.

This review carefully examined ten higher-quality (randomised-controlled) clinical trials, which involved more than 1,100 patients with COVID-19 being treated with ivermectin.

The researchers excluded many of the low-quality (observational) studies some commentators have used to support ivermectin as a COVID-19 treatment. This was because observational studies cannot control other clinical factors that might influence how people respond to COVID-19, such as other treatments and supportive care.

This major review concluded ivermectin did not reduce death from any cause, the length of stay in hospital or people’s ability to clear the virus. The review also said ivermectin was safe but “not a viable option” to treat COVID-19.

Read more: Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it[15]

But what about the withdrawn study?

In recent months, we heard the seemingly promising results from a large randomised trial[16], which was posted online as a pre-print[17] and had not been independently verified (peer reviewed).

This study stood out because it found ivermectin led to “a substantial improvement and reduction in mortality rate in ivermectin treated groups” — by 90%.

However, the excitement was tempered when the pre-print was withdrawn[18] pending a “formal investigation”. Significant questions were asked[19] about the nature of the primary data on which the study was based and whether some of the paper had been plagiarised, among other issues. This called into question[20] the spectacular positive result for ivermectin.

The trial and publication are still under investigation.

Read more: Stopping, blocking and dampening – how Aussie drugs in the pipeline could treat COVID-19[21]

Surely, that’s the end of ivermectin now?

But the ivermectin story continues. Researchers at the University of Oxford announced in June they would be starting another ivermectin trial[22], called PRINCIPLE[23].

This high-quality trial will involve investigating treatments for people at more risk of serious COVID-19. So far the trial has recruited more than 5,000 volunteers from across the UK. Another part of the trial (into another potential COVID-19 therapy) has already reported results[24].

This new ivermectin trial is just starting and will compare a three-day treatment of ivermectin in people within the first 14 days of COVID-19 symptoms, or having a positive test, with those having usual care. The trial is expected to report its results in the coming months.

What next?

Ivermectin remains a medicine of interest for treating and preventing COVID-19. Yet, key questions remain including the best ivermectin dose, how long ivermectin should be taken and when it should be given to people with COVID based on their stage of infection and illness.

Until then, getting vaccinated[25] will give you the best chance of avoiding severe COVID rather than waiting for a COVID treatment, which may or may not be shown to work.

Read more: How well do COVID vaccines work in the real world?[26]

References

  1. ^ Ivermectin (theconversation.com)
  2. ^ not enough evidence (theconversation.com)
  3. ^ some doctors (www1.racgp.org.au)
  4. ^ touting its benefits (www.sbs.com.au)
  5. ^ withdrawn (www.theguardian.com)
  6. ^ How to deal with the Craig Kelly in your life: a guide to tackling coronavirus contrarians (theconversation.com)
  7. ^ isolated cells (www.sciencedirect.com)
  8. ^ animals (www.biorxiv.org)
  9. ^ very high concentrations (www.ncbi.nlm.nih.gov)
  10. ^ National COVID-19 Clinical Evidence Taskforce (covid19evidence.net.au)
  11. ^ World Health Organization (www.who.int)
  12. ^ clinical trials (app.magicapp.org)
  13. ^ Ivermectin is still not a miracle cure for COVID-19, despite what you may have read (theconversation.com)
  14. ^ most robust summary of the evidence (academic.oup.com)
  15. ^ Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it (theconversation.com)
  16. ^ large randomised trial (www.researchsquare.com)
  17. ^ pre-print (www.thelancet.com)
  18. ^ pre-print was withdrawn (www.theguardian.com)
  19. ^ Significant questions were asked (steamtraen.blogspot.com)
  20. ^ called into question (grftr.news)
  21. ^ Stopping, blocking and dampening – how Aussie drugs in the pipeline could treat COVID-19 (theconversation.com)
  22. ^ another ivermectin trial (www.principletrial.org)
  23. ^ PRINCIPLE (www.principletrial.org)
  24. ^ results (www.principletrial.org)
  25. ^ getting vaccinated (www.mja.com.au)
  26. ^ How well do COVID vaccines work in the real world? (theconversation.com)

Read more https://theconversation.com/a-major-ivermectin-study-has-been-withdrawn-so-what-now-for-the-controversial-drug-164627

Times Magazine

Headless CMS in Digital Twins and 3D Product Experiences

Image by freepik As the metaverse becomes more advanced and accessible, it's clear that multiple sectors will use digital twins and 3D product experiences to visualize, connect, and streamline efforts better. A digital twin is a virtual replica of ...

The Decline of Hyper-Casual: How Mid-Core Mobile Games Took Over in 2025

In recent years, the mobile gaming landscape has undergone a significant transformation, with mid-core mobile games emerging as the dominant force in app stores by 2025. This shift is underpinned by changing user habits and evolving monetization tr...

Understanding ITIL 4 and PRINCE2 Project Management Synergy

Key Highlights ITIL 4 focuses on IT service management, emphasising continual improvement and value creation through modern digital transformation approaches. PRINCE2 project management supports systematic planning and execution of projects wit...

What AI Adoption Means for the Future of Workplace Risk Management

Image by freepik As industrial operations become more complex and fast-paced, the risks faced by workers and employers alike continue to grow. Traditional safety models—reliant on manual oversight, reactive investigations, and standardised checklist...

From Beach Bops to Alpine Anthems: Your Sonos Survival Guide for a Long Weekend Escape

Alright, fellow adventurers and relaxation enthusiasts! So, you've packed your bags, charged your devices, and mentally prepared for that glorious King's Birthday long weekend. But hold on, are you really ready? Because a true long weekend warrior kn...

Effective Commercial Pest Control Solutions for a Safer Workplace

Keeping a workplace clean, safe, and free from pests is essential for maintaining productivity, protecting employee health, and upholding a company's reputation. Pests pose health risks, can cause structural damage, and can lead to serious legal an...

The Times Features

Duke of Dural to Get Rooftop Bar as New Owners Invest in Venue Upgrade

The Duke of Dural, in Sydney’s north-west, is set for a major uplift under new ownership, following its acquisition by hospitality group Good Beer Company this week. Led by resp...

Prefab’s Second Life: Why Australia’s Backyard Boom Needs a Circular Makeover

The humble granny flat is being reimagined not just as a fix for housing shortages, but as a cornerstone of circular, factory-built architecture. But are our systems ready to s...

Melbourne’s Burglary Boom: Break-Ins Surge Nearly 25%

Victorian homeowners are being warned to act now, as rising break-ins and falling arrest rates paint a worrying picture for suburban safety. Melbourne residents are facing an ...

Exploring the Curriculum at a Modern Junior School in Melbourne

Key Highlights The curriculum at junior schools emphasises whole-person development, catering to children’s physical, emotional, and intellectual needs. It ensures early year...

Distressed by all the bad news? Here’s how to stay informed but still look after yourself

If you’re feeling like the news is particularly bad at the moment, you’re not alone. But many of us can’t look away – and don’t want to. Engaging with news can help us make ...

The Role of Your GP in Creating a Chronic Disease Management Plan That Works

Living with a long-term condition, whether that is diabetes, asthma, arthritis or heart disease, means making hundreds of small decisions every day. You plan your diet against m...